anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE AND DESIGN: Annexin A1 (ANXA1) plays a role in maintaining intestinal hemostasis, especially following mucosal inflammation. The published data about ANXA1 was derived from experimental animal models where there is an overlapping between epithelial and immune cells. There is no in vitro gut epithelial model that can assess the direct effect of ANXA1 on the gut epithelium.
METHODS: We developed high-throughput stem-cell-based murine epithelial cells and bacterial lipopolysaccharides (LPS) were used to induce inflammation. The impact of ANXA1 and its functional part (Ac2-26) was evaluated in the inflamed model. Intestinal integrity was assessed by the transepithelial electrical resistance (TEER), and FITC-Dextran permeability. Epithelial junction proteins were assessed using confocal microscopy and RT-qPCR. Inflammatory cytokines were evaluated by RT-qPCR and ELISA.
RESULTS: LPS challenge mediated a damage in the epithelial cells as shown by a drop in the TEER and an increase in FITC-dextran permeability; reduced the expression of epithelial junctional proteins (Occludin, ZO-1, and Cadherin) and increased the expression of the gut leaky protein, Claudin - 2. ANXA1 and Ac2-26 treatment reduced the previous damaging effects. In addition, ANXA1 and Ac2-26 inhibited the inflammatory responses mediated by the LPS and increased the transcription of the anti-inflammatory cytokine, IL-10.
CONCLUSION: ANXA1 and Ac2-26 directly protect the epithelial integrity by affecting the expression of epithelial junction and inflammatory markers. The inflamed gut model is a reliable tool to study intestinal inflammatory diseases, and to evaluate the efficacy of potential anti-inflammatory drugs and the screening of new drugs that could be candidates for inflammatory bowel disease.
Dysmenorrhea, the most common gynecological pain syndrome reported in women, is understudied in refugee communities. In addition, the association between dysmenorrhea self-medication and mental health symptoms in this population is poorly understood. We aimed to examine whether the use of dysmenorrhea analgesic self-medications and other clinical factors are associated with post-traumatic stress disorder (PTSD), depression, anxiety and insomnia severity in female war refugees residing in Zaatari Camp. This study followed a cross-sectional design and was performed on a cohort of women with predefined inclusion criteria. The severity of PTSD, depression, anxiety and insomnia were assessed using Davidson Trauma Scale, the Patient Health Questionnaire-9, the General Anxiety Disorder-7, and the Arabic version of the Insomnia Severity Index, respectively. Data were analysed from 386 participants. Using OTC paracetamol was significantly associated with higher PTSD severity (B=4.16, t= 2.43, p=0.01), and severe depression (OR=1.88, 95% CI= 1.07-3.28, p=0.03), while OTC non-steroidal anti-inflammatory drugs (NSAIDs) was significantly associated with severe insomnia (OR=1.62, 95% CI= 1.05-2.49, p= 0.02). In conclusion, self-medication with analgesics was correlated with poor mental health; close medical and psychiatric follow-up are required to supervise pain self-medication and implement non-pharmacological strategies to manage dysmenorrhea in this fragile community.
PROBLEM TO BE SOLVED: To obtain an improving agent which improves the utilizability of oligosaccharides selectively by bifidobacateria by including substances selected from propionic acid bacteria, lactic acid bacteria, naphthoquinone derivatives and naphthalene derivatives as active ingredients. SOLUTION: This reforming agent is obtained by including substances selected from (A) propionic acid bacteria, e.g. propionic acid bacteria for cheese starter, (B) lactic acid bacteria, e.g. lactic acid bacteria belonging to the genus Enterococcus or Lactococcus, (C) 1,4-naphthoquinone derivatives (e.g. α- naphthoquinone, 2-hydroxy-1,4-naphthoquinone and the like) or (D) naphthalene derivatives (e.g. 1,4-naphthalene dicarboxylic acid and the like). On the above ingredients A and B, in addition to the isolated bacteria itself, cultured cells obtained by cultivation, bacteria itself isolated from the cultured cells, cultured media (cultured supernatants), treated products (concentrates, paste products, dry products, dilute products or the like) can also be suitably used.
Participants took sildenafil citrate 50 mg as needed for sexual activity (on demand), no more than once daily, according to psychiatric prescription. Sildenafil citrate was taken with a glass of water on an empty stomach (at least 2 hours after eating). Participants met with a psychiatrist every month for 30-minutes to report adverse effects and to obtain the following month's dosage of four pills.
The present invention relates to a compound dragon's blood drug and a preparation method thereof. The drug mainly contains dragon's blood, powdered notoginseng and trace borneol. The preparation method comprises the steps that the dragon's blood and the notoginseng as medicinal materials are respectively selected and pulverized to extract effective components, and a dragon's blood powder extract and a powdered notoginseng extract are pulverized and then are mixed; the drug is prepared by adding and mixing a trace borneol powder. The drug can be prepared into capsules, powders, tablets, oral liquid and injections on the basis of the preparation method; the purity of the dragon's blood extract can reach more than 90%, and the total saponins of the notoginseng are larger than 50%. Toxicological experiments, pharmacological experiments and pharmacodynamical experiments conducted by authoritative organizations prove that The present invention has the advantages of no toxic or side effect and use safety, and has the effects of activating blood circulation to dissipate blood stasis, freeing the orifices and stopping pain; the drug is suitable for signs of coronary heart disease, angina pectoris, etc. such as chest impediment, heart pain, oppression in chest, stabbing pain, etc. caused by stagnation of heart blood, and the curative effects of the drug is obviously superior to those of a compound red sage root drug; the drug is twenty-fourth to seventeenth the price of a western drug with the same effects.
Patients in the WG were provided warm water at the 2nd postoperative hour on the day of surgery. Patients in the WG were evaluated at T0, T1, T2, and T3 and data were recorded on a data collection form. The onset of bowel sounds and flatus requires the initiation of oral fluid and nutrient intake. No other water or food was provided to patients who had no bowel sounds or flatus other than warm water.
As a versatile element for maintaining homeostasis, the chemokine system has been reported to be implicated in the pathogenesis of immune thrombocytopenia (ITP). However, research pertaining to chemokine receptors and related ligands in adult ITP is still limited. The states of several typical chemokine receptors and cognate ligands in the circulation were comparatively assessed through various methodologies. Multiple variable analyses of correlation matrixes were conducted to characterize the correlation signatures of various chemokine receptors or candidate ligands with platelet counts. Our data illustrated a significant decrease in relative CXCR3 expression and elevated plasma levels of CXCL4, 9-11, 13, and CCL3 chemokines in ITP patients with varied platelet counts. Flow cytometry assays revealed eminently diminished CXCR3 levels on T and B lymphocytes and increased CXCR5 on cytotoxic T cell (Tc) subsets in ITP patients with certain platelet counts. Meanwhile, circulating CX3CR1 levels were markedly higher on T cells with a concomitant increase in plasma CX3CL1 level in ITP patients, highlighting the importance of aberrant alterations of the CX3CR1-CX3CL1 axis in ITP pathogenesis. Spearman's correlation analyses revealed a strong positive association of peripheral CXCL4 mRNA level, and negative correlations of plasma CXCL4 concentration and certain chemokine receptors with platelet counts, which might serve as a potential biomarker of platelet destruction in ITP development. Overall, these results indicate that the differential expression patterns and distinct activation states of peripheral chemokine network, and the subsequent expansion of circulating CXCR5+ Tc cells and CX3CR1+ T cells, may be a hallmark during ITP progression, which ultimately contributes to thrombocytopenia in ITP patients.
Methods and kits are provided for diagnosis of specific cancerous conditions. The invention features a method for diagnosis of a condition in a patient associated with an elevated level of telomerase activity within a cell. The method involves determining the presence or amount of telomerase within the cells in the patient, e.g. by the use of the polymerase chain reaction. In one embodiment of the invention, the condition associated with elevated telomerase activity is chosen from prostate cancer, breast cancer, colon cancer, renal cancer, ovarian/cervical cancer, lung cancer, and leukemia. The invention allows cancer to be detected even in tissues and cells which are not positive by pathology.
OBJECTIVES: I. Compare the overall survival of surgically resected patients with limited stage IIIA non-small cell lung cancer who are treated by postoperative chemotherapy with or without adjuvant radiotherapy. II. Compare failure free survival of these patients. III. Describe the patterns of local and distant recurrence in these patients. IV. Determine the toxicities associated with chemotherapy with or without adjuvant radiotherapy in these patients.

OUTLINE: This is a randomized, multicenter study. Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients are randomized into one of two treatment arms.
PROBLEM TO BE SOLVED: To accurately remove a miscellaneous wave derived from an electrocardiogram mixedly existing in brain waves. SOLUTION: A brain wave input device 1 derives brain waves from the head of a subject to be converted into a digital signal. An electrocardiogram input device 2 derives an electrocardiogram from the body of the subject in synchronism with the brain wave input device 1 to be converted into a digital signal. A successively additively averaging means 3 stores a result in the additive average result storage part 8 of the temporary storage device 5 by independently, successively, additively averaging digital signals of brain waves and an electrocardiogram.  An influence factor calculating means 4 stores a rate at which an electrocardiogram waveform is mixed in a brain wave waveform in the influence coefficient storage part 9 of the temporary storage part 5 as an influence coefficient by dividing an average value of amplitude of the brain wave waveform calculated by the successively additively averaging means 3 by an average value of amplitude of the electrocardiogram waveform. An electrocardiogram removing means 6 removes a miscellaneous wave derived from the electrocardiogram by substracting a value by multiplying the electrocardiogram waveform by the influence coefficient from the brain wave waveform. Actual brain waves from which the miscellaneous wave derived from the electrocardiogram is removed and the electrocardiogram waveform, are outputted to an output device 7.
INTRODUCTION: Noninvasive ventilation (NIV) is widely used for sequential extubation in patients with chronic obstructive pulmonary disease (COPD). However, NIV may cause many adverse events such as claustrophobia, facial skin compression, air leakage, bloating, and even reflux aspiration, resulting in poor patient compliance/tolerance and high failure rate, especially for older adults who are at high risk of communication difficulties and consciousness disorder. High-flow nasal cannula (HFNC) oxygen therapy is a new alternative support to NIV, but whether it can effectively reduce the rate of re-intubation after extubation in elderly patients with COPD remains controversial. The purpose of this study is to explore the safety and efficacy of HFNC versus NIV for elderly COPD patients after extubation.
METHODS AND ANALYSIS: This study is an investigator-initiated, single-center, prospective, non-inferior, randomized controlled trial. Elderly patients (age > 65 years) who have received invasive ventilation and was diagnosed with COPD will be randomly assigned to HFNC group or NIV group immediately after extubation with a planned enrollment of 168 patients. The primary outcomes will be reintubation rates at 72 h and 7 days after extubation. Secondary outcomes will include treatment failure, post-extubation vital signs and arterial blood gases, the scores of compliance and comfort of patients, duration of respiratory support after extubation, respiratory support related adverse events, sleep quality scores, usage of sedative and analgesic drugs after extubation, and the incidence of delirium. Additionally, clinical outcomes such as ventilator-free days at 28 days post-randomization, tracheotomy rate, duration of intensive care unit (ICU) and hospital stay, ICU and hospital mortality will be evaluated.
ETHICS AND DISSEMINATION: This study has been approved by the Ethics Committee of West China Hospital of Sichuan University (2023-2284). Informed consent is required. It is expected that a follow-up randomized controlled trial will be conducted. The results will be submitted for publication in a peer-reviewed journal and presented at one or more scientific conferences.
TRIAL REGISTRATION: The study was retrospectively registered at ClinicalTrials.gov (ChiCTR2400087312).
FIELD: medicine. ^ SUBSTANCE: invention relates to field of veterinary. Method includes immunisation by inactivated vaccines. For immunisation used is associated inactivated vaccine from equal parts of vaccine against salmonellosis abortion from strain of bacteria Sal. abortus equi "æ-12" and inactivated vaccine against horse rhinopneumonia from strain of rhinopneumonia CB/69 virus. ^ EFFECT: method makes it possible to increase vaccination efficiency due to creation of immunity of high tension.
NEW MATERIAL:(Z)-2-Isopropenyl-5-methyl-3-hexen-1-ol of formulaI. USE:Synthetic intermediate of tetrahydrolavandulol which is used as a perfume. Further, it has floral smell by itself and is used as a perfume. It is also used as a synthetic intermediate of drugs and agricultural chemicals. PREPARATION:A lower alkyl ester of chrysanthemum-monocarboxylic acid is subjective to thermal cleavage under normal or reduced pressure at 400-600 deg.C to give a substituted diene-carboxylic acid ester of formula II (R is lower alkyl). Then, the lower alkoxycarbonyl group in the compound of formula II is selectively reduced into methylol to give the compound of formulaI. As a reducing agent for the above reaction, is used an aluminum hydride or boron hydride compound.
<P>PROBLEM TO BE SOLVED: To prevent a leakage of privacy information in a system for managing a processing history to which different management objects mutually relate.  <P>SOLUTION: A wireless tag unit 110 storing secret diagnostic treatment agent ID information, in which diagnostic treatment agent ID information for identifying a diagnostic treatment agent is made secret, is attached to the diagnostic treatment agent concerned, and also, a barcode presentation portion 120 capable of outputting patient ID information, etc. for identifying a patient is attached to the patient concerned. Here, the secret diagnostic treatment agent ID information in the wireless tag unit 110 is updated at the time determined by an arbitrary set condition. Then, when a treatment action is taken to the patient to which the diagnostic treatment agent is used, a database indicating the treatment history is implemented using the secret diagnostic treatment agent ID information, being read out from the wireless tag unit 110 attached to the diagnostic treatment agent concerned, and patient ID information, being read from the barcode presentation portion 120 attached to the patient concerned.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The invention discloses a protein capable of combining with vp60 protein of rabbit hemorrhagic disease virus and use thereof. The protein is characterized by at least containing a sequence represented by SEQ ID No.1. In the invention, the protein 215M22 kappa1 which can interact with the vp60 protein of rabbit hemorrhagic disease virus is fished out from a rabbit liver tissue cDNA library by a yeast twohybrid technique. Through coimmunoprecipitation tests, the protein is proved in vitro to be capable of combining with virions, and purified kappa 1 protein can inhibit the agglutination effect of viral antigens on human 'O' type blood cells. After the protein is inoculated into an RHDV antibody negative rabbit together with the rabbit hemorrhagic disease virus for 8 days, the rabbit is still alive and appears healthy, and the results of pathological anatomy and biopsy indicate the organs are normal. The protein kappa1 can be used in the preparation of medicines for treating rabbit hemorrhagic disease.
The invention relates to a method for producing welded or hot-sealed seal-edge bags. The contents of said bags are an exactly dosed portion of a preparation of an substrate that produces gas in an aqueous medium. The seal-edge bag is filled with the content during the production. The invention is characterised in that a string of a carrier foil is withdrawn from a supply roll using conveying means and is conveyed to a filling station on the conveying means. An exactly dosed portion of the contents is applied to the carrier foil in the filling station when said portion runs cyclically in respect to said carrier foil and over certain areas. The portions are then covered with a covering foil which can be detached from the supply roll. The two superimposed foils are welded or hot-sealed together, first cross-wise in relation to the direction of conveyance and when conveyance continues are welded or hot-sealed together on the longitudinally extending edges thereof and whereupon said they are once again welded or hot-sealed together cross-wise in relation to the direction of conveyance, whereby bags are formed that have sealed edges all around. The foils are then separated by cross-punching devices.
On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.
18 patients diagnosed as definite ALS according to the El Escorial criteria will be recruited during two years. The patients will be divided into 3 groups with different severity. Each group will be less compromised than the group that went before them. Their breathing measurements must be at least 60%. Subjects will receive injections of the human foetal neural stem cells into the spinal cord. A variety of tests and examinations will take place every month for the first year and every three months for the next two in order to monitor the course of the disease and the adverse events.
The null hypothesis for this study is that there is no difference in bone ridge width and height changes 4 months following extraction and alveolar ridge preservation at sites that undergo immediate post-extraction socket expansion or no immediate post-extraction ridge width change. Patients of the Graduate Periodontics Clinic at Marquette University School of Dentistry scheduled for extraction, bone graft and resorbable membrane will be recruited for this study.

After providing informed consent and prior to local anesthesia and extraction, the following parameters will be recorded: age, gender, race, medical history, medications, tooth site, reason for extraction and tooth mobility. Gingival width will be recorded prior to local anesthesia and extraction, and at 4 months. Gingival thickness will be recorded after local anesthesia and prior to extraction, and at 4 months. Buccolingual ridge width and ridge height will be recorded immediately before, immediately after extraction, and at 4 months. Immediately after extraction, the following measurements will be recorded: buccal bone thickness, number of roots, root length and width, instruments used for extraction, need for flap elevation, duration of extraction, anesthetic amount, type and approach, and operator experience.
RFA was performed the same as RFA Arm.Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective patients who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Patients in the immunotherapy group received 5\*10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. They were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving RFA, followed by 6-9 treatments during 6 months to 2 years after receiving RFA.
The frenectomy procedure will be performed under local infiltrative anesthesia, specifically articaine hydrochloric acid with epinephrine 1:100,000. A straight hemostat, similar to that used in the C group, will be employed to secure the frenum. Laser energy will be applied to the upper and lower sections of the frenum adjacent to the hemostat, utilizing a diode laser device equipped with a 400 µm diameter, plain-ended optical fiber tip. Frenectomy will performed with a 980 nm diode laser with 1.7 W power in continuous wave mode.The wound site will be allowed to heal by secondary intention without the application of sutures.
In one aspect, a method of displaying patient information comprising, collecting vitals from plurality of patients and displaying pattern having plurality of clusters on display device, representing plurality of patients. Each cluster in plurality of clusters comprises a set of display segments representing a corresponding set of vitals collected from a patient. In an embodiment, the display segments are displayed to provide visually distinguishable tones indicating the different critical levels of respective vitals. In another embodiment, plurality of first set of vitals is collected from the corresponding plurality of wearable device which is attached to the body of plurality of patients. Also, plurality of first set of vitals is transferred to the corresponding plurality of mobile device which is in possession of plurality of patients. Further, plurality of the first set of vital is transferred from the mobile devices to a server forming the vitals.